Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
-
Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Apr 16, 2021Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...
-
Mar 16, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research...
-
Mar 5, 2021- Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company's robust Alzheimer's disease (AD) pipeline, including...
Jan 29, 2021The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021CAMBRIDGE, Mass. and TOKYO, January 29, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Dec 7, 2020Key data results:
Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference....
-
Dec 1, 2020EMBARGOED UNTIL: 9:00 AM EST on December 4
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society (AES) Annual Meeting to be held from December...
-
Nov 2, 2020Nine presentations will highlight Eisai's investigational novel therapies being studied to treat Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including...
-
Sep 30, 2020Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies
Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 clinical study, MOMENTUM 1 (Study 304, NCT number pending),...
-
Aug 28, 2020New analyses of long-term data explores the efficacy and safety of DAYVIGO over 12 months among adults ages 65 and older and in perimenopausal women as well as fatigue severity
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced findings from several post hoc analyses of DAYVIGO™ from the Phase 3 SUNRISE 1 and 2 clinical studies and...
-
Aug 24, 2020Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual...
Aug 7, 2020• Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 • If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s diseaseCAMBRIDGE, Mass. and TOKYO, August 7, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Jul 24, 2020- One oral presentation and eight posters, highlighting Eisai's investigational novel therapies being studied to treat Alzheimer's disease (AD) and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's robust AD pipeline, including BAN2401 and...
-
Jul 13, 2020
The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United...
-
Jul 8, 2020If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, July 8, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics...
-
Jun 1, 2020
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by...
-
Feb 13, 2020
Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being...
-
Dec 27, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3...
-
Dec 23, 2019Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the U.S. Food and Drug Administration (FDA) approved DAYVIGO™ (lemborexant) 5 mg and 10 mg for the treatment of...
-
Dec 10, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that new data findings for two investigational assets in its robust dementia pipeline were presented at the 12th...
-
Dec 9, 2019Eisai presents key data at the 2019 American Epilepsy Society Annual Meeting
Eisai Inc. presented the latest healthcare economic (HCEI) data for FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore, Maryland. Cumulatively, more than...
-
Dec 9, 2019Key data results:
Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore....
-
Dec 2, 2019New Data from Eisai's Robust Dementia Pipeline Will Be Shared, Including Analyses of Investigational Alzheimer's Disease Compounds and Diagnostic Methods
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including BAN2401, lemborexant and diagnostics methods, will...
-
Nov 25, 2019Key presentations include:
Eisai Inc. today will present FYCOMPA® (perampanel) CIII data on convulsive seizure freedom and additional analyses of FYCOMPA at the upcoming American Epilepsy Society Annual Meeting taking...
-
Nov 12, 2019Ella the Jellyfish Brings Comfort and Support to Children with LGS as well as their Families and Caregivers
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). The...
- Oct 22, 2019New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints
Cambridge, Mass. and Tokyo, Japan – October 22, 2019 – Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that, after consulting with the U.S. Food and Drug...
-
Sep 27, 2019Analysis of 12-month data from Phase 3 SUNRISE 2 assessed the long-term effectiveness and safety of lemborexant in adults with insomnia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced new effectiveness and safety data from the Phase 3 clinical development program for lemborexant, an...
-
Sep 24, 2019Insomnia or Sleeping Difficulties Negatively Impact Household Cohabitants in Unexpected Ways
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from its company-sponsored survey, titled "How America Sleeps and Wakes," was presented at the 2019...
-
Sep 19, 2019Oral Presentation about Results from First Phase 3 Head-to-Head Study with Pre-specified Endpoints vs. Zolpidem ER (SUNRISE 1)
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that new long-term, Phase 3 data and additional analyses of lemborexant will be highlighted in eight...
-
Sep 13, 2019Discontinuation of studies based on Data Safety Monitoring Board recommendation
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Jul 11, 2019
In the news release, New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's...
-
Jul 9, 2019New Research Center Focused on Immunotherapy for Dementia
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., announced today the opening of its Eisai Center for Genetics Guided Dementia Discovery ("G2D2"), a new exploratory research facility located in...
-
Jun 25, 2019- Results of the FREEDOM Study (Study 342) presented at the 33rd International Epilepsy Congress (IEC)
Eisai Inc. today announced results from its FREEDOM Study (Study 342), a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® (perampanel)...
-
Jun 13, 2019-Results from the FREEDOM study, evaluating seizure freedom rates of FYCOMPA in new onset patients, including analyses at the 4 mg/day dose
Eisai Inc. today announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the...
-
Jun 11, 2019New Phase 1 study on investigational treatment explores safety of lemborexant in healthy adult and elderly populations, and those with mild obstructive sleep apnea
Eisai Inc. today announced data on the respiratory safety of investigational lemborexant with multiple and single dosing in healthy adult and elderly individuals, as well as in those with mild...
-
Jun 11, 2019New analyses presented at SLEEP 2019 evaluated impact on key insomnia measures, including disease severity, sleep onset, sleep maintenance, and long-term safety, as well as next-day functioning
Eisai Inc. today announced new long-term safety and pooled analyses from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, currently...
-
May 28, 2019Data to be presented include:
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder,...
-
May 13, 2019
The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving...
-
May 9, 2019-- Eisai presents key data from three retrospective real-world analyses at the 2019 American Academy of Neurology (AAN) Annual Meeting
Eisai Inc. presented the latest clinical results on FYCOMPA® (perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the...
-
Apr 30, 2019
Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an...
-
Apr 24, 2019Presentations include:
Eisai Inc. today announced that one oral presentation and 20 poster presentations from its neurology portfolio will be featured at the American Academy of Neurology's (AAN) Annual Meeting, May...
-
Mar 22, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th...
-
Mar 22, 2019
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in...
-
Mar 11, 2019
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P. (President and CEO: Craig...
-
Feb 25, 2019- Proposed updated label includes data from CAMELLIA-TIMI 61, the first completed and largest cardiovascular outcomes trial for a weight loss agent
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to potentially update the label for BELVIQ® (lorcaserin HCl)...
-
Feb 19, 2019- Embrace2 is the first wrist-worn wearable in the field of epilepsy to be cleared as a medical device for detecting patterns that may be associated with convulsive seizures in children & adults
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Empatica Inc. announced today that they have entered into an agreement in the U.S. to co-promote the Embrace2 smartband...
-
Feb 4, 2019Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced six-month results from SUNRISE 2, a long-term Phase 3...
-
Jan 22, 2019Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult and elderly volunteers
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced the publication of a Phase 1 safety study evaluating the...
-
Jan 15, 2019
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced that a new drug application has been submitted to the U.S....